6 research outputs found
The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and Π16 melanoma resistant to doxorubicin
Aim: To study the influence of doxorubicin at low doses on antitumor action of activated (LAK) and non-activated lymphocytes from lymph nodes toward tumor cells of mice bearing doxorubicin-resistant and doxorubicin-sensitive transplantable MC-rhabdomyosarcoma and B16 melanoma. Materials and Methods: The study was carried out on BALB/c mice bearing MC-rhabdomyosarcoma and Π‘57BL/6 mice bearing Π16 melanoma. Explants, tumor cells and lymphocytes were cultivated in diffusion chambers, filters were stained with hematoxylin by Karachi, and morphology of preparations was examined. Results: At the day 7 of tumor growth in mice bearing resistant MC-rhabdomyosarcoma, non-activated lymphocytes pretreated with low-dose doxorubicin possess the highest antitumor activity, and in mice bearing doxorubicin-resistant B16 melanoma the highest antitumor activity was detected for lymphocytes after combined cultivation with IL-2 and doxorubicin. At the day 14 of tumor growth, LAK obtained from lymphocytes pretreated with doxorubicin possess the highest cytotoxic activity toward resistant tumor cells both of MC-rhabdomyosarcoma and B16 melanoma. There was no such effect in the case of sensitive tumors. Conclusion: To elevate antitumor activity of LAK toward MC-rhabdomyosarcoma and B16 melanoma cells, low doses of doxorubicin could be used at certain conditions of LAK generation.Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΌΠ°Π»ΡΡ
Π΄ΠΎΠ· Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Π° Π½Π° ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
(ΠΠΠ) ΠΈ Π½Π΅Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΌ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌ ΠΌΡΡΠ΅ΠΉ Ρ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΡΠΌΠΈ ΠΈ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΠΊ
Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Ρ ΠΏΠ΅ΡΠ΅Π²ΠΈΠ²Π½ΠΎΠΉ ΠΠ₯-ΡΠ°Π±Π΄ΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠΎΠΉ ΠΈ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠΎΠΉ Π16. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Ρ Π½Π°
ΠΌΡΡΠ°Ρ
Π»ΠΈΠ½ΠΈΠΈ BALB/c Ρ ΠΠ₯-ΡΠ°Π±Π΄ΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠΎΠΉ ΠΈ Π‘57BL/6 c ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠΎΠΉ Π16. ΠΠΊΡΠΏΠ»Π°Π½ΡΠ°ΡΡ, ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠ΅ ΠΊΠ»Π΅ΡΠΊΠΈ ΠΈ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ
ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π»ΠΈ Π² Π΄ΠΈΡΡΡΠ·ΠΈΠΎΠ½Π½ΡΡ
ΠΊΠ°ΠΌΠ΅ΡΠ°Ρ
ΠΈ ΠΎΠΊΡΠ°ΡΠΊΠΎΠΉ ΡΠΈΠ»ΡΡΡΠΎΠ² Π³Π΅ΠΌΠ°ΡΠΎΠΊΡΠΈΠ»ΠΈΠ½ΠΎΠΌ ΠΏΠΎ ΠΠ°ΡΠ°ΡΡΠΈ. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΡΡ
ΠΊΠ°ΡΡΠΈΠ½Ρ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Ρ ΡΡΠ΅ΡΠΎΠΌ ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² ΡΠΎΡΡΠ° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ
Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΈ Π½Π΅Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ»ΠΎΠ²ΠΈΡΡ
, ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ ΡΠ»Π΅Π΄ΡΡΡΠ΅Π΅.
ΠΠ° 7-Π΅ ΡΡΡΠΊΠΈ Ρ ΠΌΡΡΠ΅ΠΉ Π· ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ₯-ΡΠ°Π±Π΄ΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠΎΠΉ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΎΠ±Π»Π°Π΄Π°Π»ΠΈ
Π½Π΅Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ, ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΎΠ±ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠ΅ ΠΌΠ°Π»ΡΠΌΠΈ Π΄ΠΎΠ·Π°ΠΌΠΈ Π΄ΠΎΠΊΠΎΡΡΠ±ΠΈΡΠΈΠ½Π°, Π° Ρ ΠΌΡΡΠ΅ΠΉ Π· ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ
ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠΎΠΉ Π16 β Π»ΠΈΠΌΡΠΎΡΠΈΡΡ ΠΏΠΎΡΠ»Π΅ ΡΠΎΡΠ΅ΡΠ°Π½Π½ΠΎΠ³ΠΎ ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Ρ ΠΠ-2 ΠΈ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½ΠΎΠΌ. ΠΠ° 14-Π΅ ΡΡΡΠΊΠΈ ΡΠΎΡΡΠ° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ
Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΎΠ±Π»Π°Π΄Π°Π»ΠΈ ΠΠΠ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΈΠ· Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΎΠ±ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΡ
Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½ΠΎΠΌ, Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊΠ°ΠΊ ΠΏΠ΅ΡΠ΅Π²ΠΈΠ²Π½ΠΎΠΉ ΠΠ₯-ΡΠ°Π±Π΄ΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΡ, ΡΠ°ΠΊ ΠΈ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΡ Π16.
ΠΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠΊΠ°Π·Π°Π½Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΡΠ°ΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡ Π½Π΅ ΠΎΡΠΌΠ΅ΡΠ°Π»ΡΡ. ΠΡΠ²ΠΎΠ΄Ρ: Π΄Π»Ρ ΡΡΠΈΠ»Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ
Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΠΠ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌ ΠΠ₯-ΡΠ°Π±Π΄ΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΡ ΠΈ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΡ Π16, ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΡΡ
ΠΊ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Ρ, ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ
ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ ΠΌΠ°Π»ΡΠ΅ Π΄ΠΎΠ·Ρ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Π° ΠΏΡΠΈ ΡΠΎΠ±Π»ΡΠ΄Π΅Π½ΠΈΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΡ
ΡΡΠ»ΠΎΠ²ΠΈΠΉ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΠΠΠ
Expression of E-cadherin in drug resistant human breast cancer cells and their sensitivity to lymphokine-activated lymphocytes action
Aim: To analyze the correlation between the elevated sensitivity of drug resistant breast cancer cells to the action of lymphokine-activated lymphocytes (LAK) and expression of E-cadherin and other marker proteins by cancer cells and lymphocytes. Methods: Breast tumor explants were cultured with autologous lymphocytes in double diffusion chambers. The results were evaluated by morphological criteria of explants growth. Expression level of proteins on tumor cells was analyzed using immunohistochemical method on paraffin embedded sections, and by indirect immunofluorescence β on lymphocytes. Results: Significant decrease of E-cadherin expression and significant increase of nuclear antigen of proliferating cells expression have been detected on drug resistant malignant human breast tumor (DRHBT) cells compared with drug sensitive breast tumor (DSHBT) cells. Autologous LAK possessed the highest antitumor activity against DRHBT cells that was associated with high expression level of soybean lectin receptor. Conclusion: Malignant drug resistant tumors are characterized by reverse relation between E-cadherin expression level and their proliferative activity. Marked antitumor action of LAK against these tumors is associated with high expression level of soybean lectin receptor on the lymphocytes
Efficacy of different immunotherapy approaches toward treatment of doxorubicin-resistant and doxorubicinsensitive transplantable rhabdomyosarcoma
Aim: To evaluate the efficacy of different variants of immunotherapy, namely, adoptive LAK-therapy, vaccine therapy and their combination in vivo using transplantable murine MC-rhabdomyosarcoma resistant and sensitive to doxorubicin (Dox). Materials and Methods: The study was carried out on BALB/c mice bearing Dox-sensitive and Dox-resistant transplantable murine MC-rhabdomyosarcoma. LAK-therapy (using lymphocytes from lymph nodes of syngenic mice) was performed starting from day 7 after tumor cell transplantation for 5 days; LAK (3 x 106 cells in 0.2 ml medium) were injected in the region of tumor. The vaccine prepared on the base of tumor cell glycopeptides was administered intraperitoneally at the volume of 0.2 ml before or after tumor transplantation. Efficacy of immunotherapy was evaluated by tumor growth inhibition and life span of animals. Results: By the indexes of tumor growth inhibition and average life span, for animals bearing Dox-sensitive tumors vaccine therapy was the most effective, whilst adoptive LAK-therapy was the most effective for mice bearing Dox-resistant tumors. All applied variants of therapy β adoptive LAK-therapy, vaccine therapy and their combination were effective for treatment of mice bearing Dox-sensitive and Dox-resistant transplantable murine MC-rhabdomyosarcoma. Conclusion: The obtained data demonstrated that Dox-sensitive and Dox-resistant tumors differ by the sensitivity to different types of immunotherapy.Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π²ΠΈΠ΄ΠΎΠ² ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π° ΠΈΠΌΠ΅Π½Π½ΠΎ Π°Π΄ΠΎΠΏΡΠΈΠ²Π½ΠΎΠΉ ΠΠΠ-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅
ΠΈΡ
ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ, Π΄Π°ΡΡ ΠΎΡΠ΅Π½ΠΊΡ ΠΈΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΏΠ΅ΡΠ΅Π²ΠΈΠ²Π½ΠΎΠΉ ΠΠ₯-ΡΠ°Π±Π΄ΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΡ ΠΌΡΡΠ΅ΠΉ, ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΈ
ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Ρ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Ρ Π½Π° ΠΌΡΡΠ°Ρ
Π»ΠΈΠ½ΠΈΠΈ BALB/c Ρ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ
ΠΈ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΊ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Ρ ΠΏΠ΅ΡΠ΅Π²ΠΈΠ²Π½ΠΎΠΉ ΠΠ₯-ΡΠ°Π±Π΄ΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠΎΠΉ. ΠΠΠ-ΡΠ΅ΡΠ°ΠΏΠΈΡ (Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°ΠΌΠΈ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ²
ΡΠΈΠ½Π³Π΅Π½Π½ΡΡ
ΠΌΡΡΠ΅ΠΉ) ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π½Π°ΡΠΈΠ½Π°Ρ Ρ 7 ΡΡΡ ΠΏΠΎΡΠ»Π΅ ΠΏΠ΅ΡΠ΅Π²ΠΈΠ²ΠΊΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ Π½Π° ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ 5 Π΄Π½Π΅ΠΉ; ΠΠΠ Π²Π²ΠΎΠ΄ΠΈΠ»ΠΈ Π²
ΠΎΠ±Π»Π°ΡΡΡ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π² ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅ 3 ΠΌΠ»Π½ Π² 0,2 ΠΌΠ» ΡΡΠ΅Π΄Ρ. ΠΠ°ΠΊΡΠΈΠ½Ρ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ Π³Π»ΠΈΠΊΠΎΠΏΠ΅ΠΏΡΠΈΠ΄ΠΎΠ² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ,
Π²Π²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΌΡΡΠ°ΠΌ ΠΈΠ½ΡΡΠ°ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΠΎ Π² ΠΎΠ±ΡΠ΅ΠΌΠ΅ 0,2 ΠΌΠ» ΠΏΠΎ Π΄Π²ΡΠΌ ΡΡ
Π΅ΠΌΠ°ΠΌ: Π΄ΠΎ ΠΏΠ΅ΡΠ΅Π²ΠΈΠ²ΠΊΠΈ ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΏΠ΅ΡΠ΅Π²ΠΈΠ²ΠΊΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ. ΠΠ»ΠΈΡΠ½ΠΈΠ΅
ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ ΠΏΡΠΎΡΠ΅Π½ΡΡ ΡΠΎΡΠΌΠΎΠΆΠ΅Π½ΠΈΡ ΡΠΎΡΡΠ° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: Π΄Π°Π½Π½ΡΠ΅
ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ, ΡΡΠΎ Ρ ΠΌΡΡΠ΅ΠΉ Ρ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Ρ ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Π° Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ, Π° ΠΏΡΠΈ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ β Π°Π΄ΠΎΠΏΡΠΈΠ²Π½Π°Ρ ΠΠΠ-ΡΠ΅ΡΠ°ΠΏΠΈΡ, ΡΡΠΎ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°Π»ΠΎΡΡ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ
ΠΏΡΠΎΡΡΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΠΆΠΈΠ·Π½ΠΈ ΠΈ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΌ ΡΠΎΡΠΌΠΎΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΎΡΡΠ° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Ρ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
ΡΡΠΎΠΉ Π³ΡΡΠΏΠΏΡ. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ,
ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΠΠ-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΠΈΡ
ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°Π», ΡΡΠΎ Π²ΡΠ΅ Π΅Π΅ Π²ΠΈΠ΄Ρ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Ρ Ρ ΠΌΡΡΠ΅ΠΉ ΠΊΠ°ΠΊ Ρ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ, ΡΠ°ΠΊ ΠΈ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΊ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Ρ ΠΠ₯-ΡΠ°Π±Π΄ΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠΎΠΉ. ΠΡΠ²ΠΎΠ΄Ρ:
ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ ΡΠΎΠΌ, ΡΡΠΎ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΡΠ΅ ΠΈ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΊ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Ρ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ
ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΊ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌ Π²ΠΈΠ΄Π°ΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΡΡΠΎ, ΠΏΠΎ Π²ΡΠ΅ΠΉ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΠΈ, ΠΎΠ±ΡΡΡΠ½ΡΠ΅ΡΡΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ°ΠΌΠΈ
ΠΈΡ
Π΄Π΅ΠΉΡΡΠ²ΠΈΡ
Antitumor action of lymphokin-activated ΡΠ΅lls of patients with soft tissue sarcomas and melanomas in dependence on expression of MHC classes I and II antigenes
Aim: To study expression of major histocompatibility complex (MHC) classes Π and ΠΠ antigens and CD25, CD71, Ki-67, CD54, CD56, CD11b, PCNA on lymphocytes and tumor cells and antitumor action of lymphocytes activated with IL-2. Materials and Methods: Tumor explants (soft tissue sarcoma, n = 20, melanoma, n = 25) were co-cultivated in diffusion chambers with autologous lymphocytes; antitumor action was evaluated by morphologic patterns of explantβs growth. Expression of CD25, CD71, Ki-67, CD54, CD56, CD11b, PCNA was evaluated by the method of indirect fluorescence using respective monoclonal antibodies. Results: The highest antitumor action of lymphocytes toward soft tissue sarcoma and melanoma cells is observed if tumor cells are expressing MHC class I antigens. In the cases of soft tissue sarcoma no correlation between the level of antitumor activity of lymphocytes and expression of CD25, CD71, Ki-67, CD54, CD56, CD11b, PCNA has been found, whilst in the case of melanoma it is associated with the high level of CD11b expression. Conclusion: There is a direct correlation between sensitivity of soft tissue sarcoma and melanoma cells to action of lymphokin-activated killer cells and the level of MHC class I antigens.Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠΈΡΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π°Π½ΡΠΈΠ³Π΅Π½ΠΎΠ² Π ΠΈ ΠΠ ΠΊΠ»Π°ΡΡΠ° Π³Π»Π°Π²Π½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° Π³ΠΈΡΡΠΎΡΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΠΎΡΡΠΈ (ΠΠΠ) Π½Π° Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°Ρ
ΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
(ΡΠ°ΡΠΊΠΎΠΌΡ ΠΌΡΠ³ΠΊΠΈΡ
ΡΠΊΠ°Π½Π΅ΠΉ ΠΈ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠ° ΠΊΠΎΠΆΠΈ) ΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΈ
Π½Π΅Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΠ-2 ΠΏΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΠΎ Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ², Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΡ
ΠΏΡΠΎΡΠ΅ΠΎΠΌ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ:
ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΊΡΠΏΠ»Π°Π½ΡΠ°ΡΠΎΠ² ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ Π°ΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΡΡ
Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π² Π΄ΠΈΡΡΡΠ·ΠΈΠΎΠ½Π½ΡΡ
ΠΊΠ°ΠΌΠ΅ΡΠ°Ρ
Ρ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΠΌ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ΠΌ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΡΠΎΡΡΠ° ΡΠΊΡΠΏΠ»Π°Π½ΡΠ°ΡΠΎΠ². ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ
Π°Π½ΡΠΈΠ³Π΅Π½ΠΎΠ² CD25, CD71, Ki-67, CD54, CD56, CD11b, ΡΠ΄Π΅ΡΠ½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΠ³Π΅Π½Π° ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠΈΡΡΡΡΠΈΡ
ΠΊΠ»Π΅ΡΠΎΠΊ (ΠΠΠ-38) ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π½Π΅ΠΏΡΡΠΌΠΎΠΉ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠΈΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π°Π½ΡΠΈΡΠ΅Π». Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠ΅
ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΊΠ°ΠΊ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΡΠΊΠΎΠΌΠ°ΠΌΠΈ ΠΌΡΠ³ΠΊΠΈΡ
ΡΠΊΠ°Π½Π΅ΠΉ, ΡΠ°ΠΊ ΠΈ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠΎΠΉ ΠΏΡΠΎΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ
ΠΊ ΡΠ΅ΠΌ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΌ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌ, ΠΊΠΎΡΠΎΡΡΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΡΡ Π°Π½ΡΠΈΠ³Π΅Π½Ρ I ΠΊΠ»Π°ΡΡΠ° ΠΠΠ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΡΠΊΠ°Π·Π°Π½Π½ΡΡ
ΡΡΡΡΠΊΡΡΡ Π΄Π»Ρ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π·Π°Π²ΠΈΡΠΈΡ ΠΎΡ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ: Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ ΠΈΠ·ΡΡΠ΅Π½Π½ΡΡ
ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΡΠΊΠΎΠΌΠΎΠΉ Π½Π΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ. Π ΡΠΎ ΠΆΠ΅ Π²ΡΠ΅ΠΌΡ
Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠΎΠΉ ΡΠΎΡΠ΅ΡΠ°Π»ΠΎΡΡ Ρ Π²ΡΡΠΎΠΊΠΈΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΈΠΌΠΈ
CD11b. ΠΡΠ²ΠΎΠ΄Ρ: ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° ΠΏΡΡΠΌΠ°Ρ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π»ΠΈΠΌΡΠΎΠΊΠΈΠ½Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΡ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π°Π½ΡΠΈΠ³Π΅Π½ΠΎΠ² ΠΠΠ I ΠΊΠ»Π°ΡΡΠ° Π½Π° ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΊΠ°ΠΊ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΡ, ΡΠ°ΠΊ ΠΈ ΡΠ°ΡΠΊΠΎΠΌ